A Phase 1, Single Center, Randomized, Double-blind, Placebo-controlled, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, on the Pharmacokinetics of HRS4800 in Healthy Male Subjects
Latest Information Update: 06 Apr 2023
At a glance
- Drugs HRS 4800 (Primary)
- Indications Pain
- Focus Adverse reactions
- Sponsors Jiangsu Hengrui Medicine Co.
- 04 May 2021 New trial record